Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- KTTA
- Price
- 0.69
- Stock movement down
- -0.02 (-2.44%)
- Company name
- Pasithea Therapeutics Corp
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 15.52M
- Ent value
- 12.82M
- Price/Sales
- 23.91
- Price/Book
- 1.27
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -2934.12%
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return (CAGR)
- -52.55%
- 3 year return (CAGR)
- -62.11%
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2026-02-20
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
KTTA does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 23.91 |
| Price to Book | 1.27 |
| EV to Sales | 19.75 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 22.40M |
| EPS (TTM) | -1.81 |
| FCF per share (TTM) | -1.65 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 649.03K |
| Gross profit (TTM) | -667.25K |
| Operating income (TTM) | -13.86M |
| Net income (TTM) | -13.49M |
| EPS (TTM) | -1.81 |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | -102.81% |
| Operating margin (TTM) | -2135.61% |
| Profit margin (TTM) | -2079.18% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 4.12M |
| Net receivables | 0.00 |
| Total current assets | 5.53M |
| Goodwill | 1.26M |
| Intangible assets | 6.84M |
| Property, plant and equipment | 0.00 |
| Total assets | 13.63M |
| Accounts payable | 1.34M |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 1.38M |
| Total liabilities | 1.42M |
| Shareholder's equity | 12.21M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -12.26M |
| Capital expenditures (TTM) | 16.00 |
| Free cash flow (TTM) | -12.26M |
| Dividends paid (TTM) | 359.66M |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -110.55% |
| Return on Assets | -99.00% |
| Return on Invested Capital | -110.55% |
| Cash Return on Invested Capital | -100.42% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.70 |
| Daily high | 0.72 |
| Daily low | 0.67 |
| Daily Volume | 76K |
| All-time high | 112.00 |
| 1y analyst estimate | 3.00 |
| Beta | 0.21 |
| EPS (TTM) | -1.81 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| KTTA | S&P500 | |
| Current price drop from All-time high | -99.38% | -1.82% |
| Highest price drop | -99.74% | -56.47% |
| Date of highest drop | 21 Nov 2025 | 9 Mar 2009 |
| Avg drop from high | -87.49% | -10.84% |
| Avg time to new high | 370 days | 12 days |
| Max time to new high | 1060 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
15.52M
Marketcap category
Small-cap
Description
Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumors; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis. The company's lead development candidate is PAS-003, to treat amyotrophic lateral sclerosis. It also intends to develop PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.
Employees
4
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partner